AU2003210670A1 - Compositions and methods for the detection, diagnosis and therapy of hematogolical malignancies - Google Patents

Compositions and methods for the detection, diagnosis and therapy of hematogolical malignancies

Info

Publication number
AU2003210670A1
AU2003210670A1 AU2003210670A AU2003210670A AU2003210670A1 AU 2003210670 A1 AU2003210670 A1 AU 2003210670A1 AU 2003210670 A AU2003210670 A AU 2003210670A AU 2003210670 A AU2003210670 A AU 2003210670A AU 2003210670 A1 AU2003210670 A1 AU 2003210670A1
Authority
AU
Australia
Prior art keywords
hematogolical
malignancies
diagnosis
therapy
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2003210670A
Other versions
AU2003210670B2 (en
AU2003210670B8 (en
Inventor
Paul A. Algate
Lauren Carter
Jonathan David Clapper
Alexander Gaiger
Jane Mannion
Patricia Dianne Mcneill
Nadia Ordonez
Aijun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/057,475 priority Critical patent/US20040002068A1/en
Priority to US10/057,475 priority
Application filed by Corixa Corporation filed Critical Corixa Corporation
Priority to PCT/US2003/002353 priority patent/WO2003062401A2/en
Publication of AU2003210670A1 publication Critical patent/AU2003210670A1/en
Publication of AU2003210670B2 publication Critical patent/AU2003210670B2/en
Application granted granted Critical
Publication of AU2003210670B8 publication Critical patent/AU2003210670B8/en
Application status is Active legal-status Critical
Anticipated expiration legal-status Critical

Links

AU2003210670A 2000-03-01 2003-01-22 Compositions and methods for the detection, diagnosis and therapy of hematogolical malignancies Active AU2003210670B8 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/057,475 US20040002068A1 (en) 2000-03-01 2002-01-22 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US10/057,475 2002-01-22
PCT/US2003/002353 WO2003062401A2 (en) 2002-01-22 2003-01-22 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies

Publications (3)

Publication Number Publication Date
AU2003210670A1 true AU2003210670A1 (en) 2003-09-18
AU2003210670B2 AU2003210670B2 (en) 2008-12-04
AU2003210670B8 AU2003210670B8 (en) 2009-01-08

Family

ID=27609444

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003210670A Active AU2003210670B8 (en) 2000-03-01 2003-01-22 Compositions and methods for the detection, diagnosis and therapy of hematogolical malignancies

Country Status (15)

Country Link
US (7) US20040002068A1 (en)
EP (2) EP1975231B1 (en)
KR (1) KR101204241B1 (en)
CN (1) CN1643143B (en)
AT (1) AT519844T (en)
AU (1) AU2003210670B8 (en)
CA (1) CA2473746C (en)
CY (1) CY1112748T1 (en)
DK (1) DK1975231T3 (en)
ES (1) ES2370737T3 (en)
HK (1) HK1078327A1 (en)
NZ (1) NZ561297A (en)
PT (1) PT1975231E (en)
SI (1) SI1975231T1 (en)
WO (1) WO2003062401A2 (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166107A1 (en) * 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US7179895B2 (en) 2003-08-22 2007-02-20 Neuromed Pharmaceuticals Ltd. Rat calcium channel subunits and related probes, cell lines and methods
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
CA2546285C (en) * 2003-11-17 2015-12-29 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
US20090123413A1 (en) * 2004-08-23 2009-05-14 Britta Hardy Use of bat monoclonal antibody for immunotherapy
US20060052948A1 (en) * 2004-09-09 2006-03-09 Jorn Gorlach Method of identifying drugs, targeting moieties or diagnostics
SI1791565T1 (en) 2004-09-23 2016-08-31 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1926747A1 (en) * 2005-08-12 2008-06-04 Schering Corporation Mcp1 fusions
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
ES2324435B1 (en) * 2005-10-27 2010-05-31 Fundacion Para El Estudio De La Hematologia Y Hemoterapia De Aragon (Fehha) Procedure and device in vitro mRNA of genes involved in hematological neoplasias analysis.
SG172656A1 (en) 2006-05-30 2011-07-28 Genentech Inc Antibodies and immunoconjugates and uses therefor
EP2657253B1 (en) 2008-01-31 2017-07-19 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
AU2008276140C1 (en) 2007-07-16 2012-10-25 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
CA2728927C (en) 2008-07-01 2018-02-13 Genocea Biosciences, Inc. Antigen screening system
NZ612647A (en) 2009-03-10 2015-03-27 Biogen Idec Inc Anti-bcma antibodies
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
AU2011239507B2 (en) 2010-04-15 2015-04-09 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
AU2011265054B2 (en) 2010-06-08 2016-09-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
US8068011B1 (en) 2010-08-27 2011-11-29 Q Street, LLC System and method for interactive user-directed interfacing between handheld devices and RFID media
ES2544608T3 (en) 2010-11-17 2015-09-02 Genentech, Inc. Conjugates of the antibody and alaninyl-maytansinol
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
RU2638806C2 (en) 2011-05-12 2017-12-15 Дженентек, Инк. Lc-ms/ms method for multiple reactions monitoring to identify therapeutic antibodies in animal species using framework signature peptides
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
WO2014026277A1 (en) 2012-08-15 2014-02-20 Université de Montréal Method for identifying novel minor histocompatibility antigens
HUE035694T2 (en) 2012-10-12 2018-05-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
JP5993093B2 (en) 2012-10-12 2016-09-14 メドイミューン・リミテッドMedImmune Limited Pyrrolo benzodiazepines and their complexes
CN105050661B (en) 2012-10-12 2018-03-30 Adc疗法责任有限公司 Pyrrolo benzodiazepine - antibody conjugate
KR20150085814A (en) 2012-10-12 2015-07-24 에이디씨 테라퓨틱스 에스에이알엘 Pyrrolobenzodiazepine-antibody conjugates
JP6307519B2 (en) 2012-12-21 2018-04-04 メドイミューン・リミテッドMedImmune Limited Pyrrolo benzodiazepines and its conjugate
CA2894959A1 (en) 2012-12-21 2014-06-26 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
WO2014113490A2 (en) 2013-01-15 2014-07-24 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
WO2014113431A2 (en) * 2013-01-15 2014-07-24 Tufts Medical Center Methods and compositions for targeting immunoglobulins
JP2016507066A (en) * 2013-02-08 2016-03-07 インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ Improved diagnostic methods of multiple myeloma, chronic lymphocytic leukemia, and b-cell non-Hodgkin's lymphoma, prognostic methods, and monitoring method
EP2968585B1 (en) 2013-03-13 2018-07-18 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
NZ710746A (en) 2013-03-13 2018-11-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2015095212A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CA2918139A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
BR112016013861A2 (en) 2013-12-16 2017-10-10 Genentech Inc antibody and conjugated drug, compound, method of treatment and pharmaceutical composition
MX2016007825A (en) 2013-12-16 2016-09-07 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof.
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
JP2017527271A (en) 2014-07-21 2017-09-21 ノバルティス アーゲー Treatment of cancer using human anti bcma chimeric antigen receptor
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
JP2017531620A (en) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド Cysteine ​​engineered antibodies and conjugates
BR112017005393A2 (en) 2014-09-17 2017-12-05 Genentech Inc compound of formula I, the method of preparation of a conjugate of formula, formula A1 conjugate, composition comprising a mixture of antibody-drug conjugate compounds, pharmaceutical composition and use of a conjugate or a composition
AU2015317608A1 (en) 2014-09-17 2017-04-06 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN104388556B (en) * 2014-11-11 2016-08-24 中国人民解放军第二军医大学 Application of a long chain non-coding rna ovarian cancer in the manufacture of diagnostic or therapeutic medicament
AU2015358532A1 (en) 2014-12-03 2017-06-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
US20180044424A1 (en) 2015-02-02 2018-02-15 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US20180230193A1 (en) 2015-08-07 2018-08-16 Andreas Loew Treatment of cancer using chimeric cd3 receptor proteins
US10058613B2 (en) 2015-10-02 2018-08-28 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EP3362100A1 (en) 2015-10-16 2018-08-22 Genentech, Inc. Hindered disulfide drug conjugates
WO2017068511A1 (en) 2015-10-20 2017-04-27 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
CN108603200A (en) 2015-11-23 2018-09-28 诺华股份有限公司 Optimized lentiviral transfer vectors and uses thereof
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 Multiplexed total antibody and antibody-conjugated drug quantification assay
EP3458101A1 (en) 2016-05-20 2019-03-27 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
EP3465221A1 (en) 2016-05-27 2019-04-10 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
US20170348422A1 (en) 2016-06-06 2017-12-07 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2019060398A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Thailanstatin analogs
WO2019079569A1 (en) 2017-10-18 2019-04-25 Novartis Ag Compositions and methods for selective protein degradation
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
WO2019108900A1 (en) 2017-11-30 2019-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv Method for the detection and determination of laagmoleculire compounds and of proteins that can specifically bind these compounds, as well as the test pack.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4520019A (en) 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579945A (en) 1982-04-29 1986-04-01 Ribi Immunochem Research, Inc. Purification of trehalose dimycolates
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4505900A (en) 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4505899A (en) 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4435386A (en) 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
JPH021808B2 (en) 1982-12-24 1990-01-12 Teijin Ltd
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4673562A (en) 1983-08-19 1987-06-16 The Children's Medical Center Corporation Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4683202B1 (en) 1985-03-28 1990-11-27 Cetus Corp
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4683195B1 (en) 1986-01-30 1990-11-27 Cetus Corp
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4957858A (en) 1986-04-16 1990-09-18 The Salk Instute For Biological Studies Replicative RNA reporter systems
US4742000A (en) * 1986-05-02 1988-05-03 University Of Chicago Antibody to human progesterone receptor and diagnostic materials and methods
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
US4735792A (en) 1987-04-28 1988-04-05 The United States Of America As Represented By The United States Department Of Energy Radioiodinated maleimides and use as agents for radiolabeling antibodies
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Method and kits for the amplification and detection of nucleic acid sequences
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
EP0398880A4 (en) 1988-01-04 1990-12-27 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
AT92538T (en) 1988-01-21 1993-08-15 Genentech Inc Strengthening and detection of nucleic acid.
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
AU623642B2 (en) 1988-03-24 1992-05-21 University Of Iowa Research Foundation, The Catalytic hybridization systems for the detection of nucleic acid sequences based on their activity as cofactors in catalytic reactions in which a complementary labeled nucleic acid probe is cleaved
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biolog Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5416070A (en) 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
US4950645A (en) 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag Bispecific, oligo, mono- and oligovalent antikoerperkonstrukte, their production and use
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
KR920007887B1 (en) 1989-08-29 1992-09-18 우찌야마 히사오 Exhaust gas cleaning device for internal combustion engine
CA2039718C (en) 1989-08-31 2003-02-25 John J. Rossi Chimeric dna-rna catalytic sequences
DE69033127T2 (en) 1989-11-13 1999-10-14 Massachusetts Inst Technology Localization and characterization of the Wilms' tumor gene
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren Protein D - an IgD-binding protein FROM Haemophilus influenzae, and anvaendning this Foer analysis, vaccines and uppreningsaendamaal
US6365730B1 (en) 1990-06-19 2002-04-02 Gene Shears Pty. Limited DNA-Armed ribozymes and minizymes
JP3218637B2 (en) 1990-07-26 2001-10-15 大正製薬株式会社 Stable aqueous liposomal suspension
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (en) 1990-08-27 1999-10-06 株式会社ビタミン研究所 Multilamellar liposomes and gene trapped multilamellar liposome preparation, as well as a process for their preparation for gene transfer
US5342761A (en) * 1990-10-01 1994-08-30 Research Development Foundation Oncofetal gene, gene product and uses therefor
AT147098T (en) 1990-10-12 1997-01-15 Max Planck Gesellschaft modified ribozyme
DK0553288T3 (en) 1990-10-18 1997-12-29 Cellpro Inc An apparatus and method for collecting particulates by use of a pliable vessel
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE4216134A1 (en) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetic catalytic oligonucleotide structures
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
DE69233528D1 (en) 1991-11-25 2005-07-14 Enzon Inc A process for the production of multivalent antigen-binding proteins
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
JPH08500481A (en) 1992-05-11 1996-01-23 リボザイム・ファーマシューティカルズ・インコーポレーテッド Methods and agents for inhibiting the replication of the virus
CZ282235B6 (en) 1992-06-25 1997-06-11 Smithkline Beecham Biologicals (S.A.) Inoculation substance, process of its preparation and use
EP0786522A3 (en) 1992-07-17 1997-08-27 Ribozyme Pharm Inc
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
DK0678034T3 (en) 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induction of cytotoxic T lymphocyte responses
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
IL108367D0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
FR2702160B1 (en) 1993-03-02 1995-06-02 Biovecteurs As Synthetic particulate vector and method of preparation.
FR2704145B1 (en) 1993-04-21 1995-07-21 Pasteur Institut particulate and pharmaceutical composition containing the vector.
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5591317A (en) 1994-02-16 1997-01-07 Pitts, Jr.; M. Michael Electrostatic device for water treatment
US6017719A (en) * 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
ES2267100T5 (en) 1994-07-15 2011-04-08 Coley Pharmaceutical Group, Inc. Immunomodulatory oligonucleotides.
FR2723849B1 (en) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Method to increase the immunogenicity, the product obtained and pharmaceutical composition
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ES2140076T5 (en) 1995-04-25 2007-04-16 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol.
EP0832282A1 (en) 1995-06-02 1998-04-01 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
US5747470A (en) 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
CA2250183A1 (en) 1996-03-27 1997-10-02 Arie S. Belldegrun Psa positive regulating (psar) sequences and uses thereof
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
DE122007000021I1 (en) 1997-04-07 2007-05-24 Genentech Inc Anti-VEFG Antibodies
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
WO2000017222A1 (en) 1998-09-23 2000-03-30 Human Genome Sciences, Inc. 31 human secreted proteins
AU764211C (en) 1998-12-01 2006-03-30 Abbvie Biotherapeutics Inc. Humanized antibodies to gamma-interferon
EP1642973B1 (en) 1999-01-07 2009-07-22 ZymoGenetics, Inc. Therapeutic uses of BR43X2 soluble receptors
GEP20053685B (en) * 1999-08-17 2005-12-12 Biogen Inc BAFF Receptor (BCMA), an Immunoregulatory Agent
JP4880155B2 (en) * 1999-10-06 2012-02-22 トポターゲット スイッツァランド エスアー April receptor (bcma) and its use
JP2003532378A (en) 1999-11-29 2003-11-05 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Isolation of the five novel genes encoding novel Fc receptor type melanoma involved in the development of lymphoma / melanoma
AT511857T (en) * 2000-02-16 2011-06-15 Genentech Inc Anti-april monoclonal antibodies and their use for the treatment of immune disorders or cancer
AU4347701A (en) 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
EP2301971A1 (en) 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antibodies that bind both BCMA and TACI

Similar Documents

Publication Publication Date Title
TWI335315B (en) Preparation of butadiene and 1-butene
EP1505906B8 (en) System and methods for detecting precancerous and cancerous tissue
EP2295053B8 (en) Novel 2H-chromen-2-one-3-carboxamides for medical uses
EP1515982A4 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
ZA200206400B (en) Compositions and methods for the therapy and diagnosis of prostate cancer.
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
AU2003275311A1 (en) Solid micro-perforators and methods of use
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
AU2002305428A1 (en) Portable pressure transducer, pneumotach for use therewith, and associated methods
AU2003256813A1 (en) Medical tele-robotic system
AU2003267335A1 (en) Lbl-coated medical device and method for making the same
AU2001239832A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
IL166623A (en) Aripiprazole complex, formulations comprising the same and uses thereof
ZA200408895B (en) Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith.
AU2003283786A1 (en) Surgical tools and techniques for stimulation
AU2003293045A1 (en) Systems and methods for respiration measurement
AU2002339865A1 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
PL354093A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2003262747A1 (en) Compounds, compositions, and methods
AU2003293345A1 (en) Detection of disordered breathing
AU2003233010A8 (en) Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
AU2003223207A1 (en) SCDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003220348A1 (en) Ct integrated respiratory monitor
AU2003265242A1 (en) Compounds, compositions, and methods